Formation of an active form of the interleukin-2/ 15 receptor β-chain by insertion of the intracisternal A particle in a radiation-induced mouse thymic lymphoma and its role in tumorigenesis

Molecular Carcinogenesis

Volumn 37, Issue 2, 2003, Pages 110-119

  Ukai, Hideki ^a   Ishii Oba, Hiroko ^b   Ukai Tadenuma, Maki ^c   Ogiu, Toshiaki ^b   Tsuji, Hideo ^b  

^a JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

^b NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^c CHIBA UNIVERSITY   (Japan)

Author keywords

Constitutive activation; Interleukin 2 15 receptor chain; Intracisternal A particle; Thymic lymphoma

Indexed keywords

CHIMERIC PROTEIN; GAG PROTEIN; INTERLEUKIN 15 RECEPTOR; INTERLEUKIN 2; POL PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; IMMUNOPATHOGENESIS; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; RADIATION CARCINOGENESIS; RETROPOSON; SCID MOUSE; SIGNAL TRANSDUCTION; THYMUS LYMPHOMA;

AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; DEFECTIVE VIRUSES; GENE PRODUCTS, GAG; GENES, INTRACISTERNAL A-PARTICLE; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR BETA SUBUNIT; LYMPHOMA; MICE; MICE, SCID; MOLECULAR SEQUENCE DATA; MUTAGENESIS, INSERTIONAL; NEOPLASMS, RADIATION-INDUCED; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; THYMUS NEOPLASMS; TUMOR CELLS, CULTURED; VIRUS INTEGRATION;

INSERTION SEQUENCES; INTRACISTERNAL A-PARTICLES;

EID: 0037533704     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/mc.10128     Document Type: Article

References (49)

1. Taniguchi T. Cytokine signaling through nonreceptor protein tyrosine kinases. Science 1995;268:251-255.
2. Lang RA, Burgess AW. Autocrine growth factors and tumourigenic transformation. Immunol Today 1990;11:244-249.
3. Davies DR, Wlodawer A. Cytokines and their receptor complexes. FASEB J 1995;9:50-56.
4. Kondo M, Takeshita T, Ishii N, et al. Sharing of the interleukin-2 (IL-2) receptor gamma chain between receptors for IL-2 and IL-4. Science 1993;262:1874-1877.
5. Kondo M, Takeshita T, Higuchi M, et al. Functional participation of the IL-2 receptor gamma chain in IL-7 receptor complexes. Science 1994;263:1453-1454.
6. Giri JG, Ahdieh M, Eisenman J, et al. Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBOJ 1994;13:2822-2830.
7. Grabstein KH, Eisenman J, Shanebeck K, et al. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 1994;264:965-968.
8. Noguchi M, Nakamura Y, Russell SM, et al. Interleukin-2 receptor gamma chain: A functional component of the interleukin-7 receptor. Science 1993;262:1877-1880.
9. Russell SM, Keegan AD, Harada N, et al. Interleukin-2 receptor gamma chain: A functional component of the interleukin-4 receptor. Science 1993;262:1880-1883.
10. Kimura Y, Takeshita T, Kondo M, et al. Sharing of the IL-2 receptor gamma chain with the functional IL-9 receptor complex. Int Immunol 1995;7:115-120.
11. Arima N, Daitoku Y, Ohgaki S, et al. Autocrine growth of interleukin 2-producing leukemic cells in a patient with adult T cell leukemia. Blood 1986;68:779-782.
12. Gootenberg JE, Ruscetti FW, Mier JW, Gazdar A, Gallo RC. Human cutaneous T cell lymphoma and leukemia cell lines produce and respond to T cell growth factor. J Exp Med 1981;154:1403-1418.
13. Maruyama M, Shibuya H, Harada H, et al. Evidence for aberrant activation of the interleukin-2 autocrine loop by HTLV-1-encoded p40x and T3/Ti complex triggering. Cell 1987;48:343-350.
14. Yamada G, Kitamura Y, Sonoda H, et al. Retroviral expression of the human IL-2 gene in a murine T cell line results in cell growth autonomy and tumorigenicity. EMBO J 1987;6:2705-2709.
15. Karasuyama H, Tohyama N, Tada T. Autocrine growth and tumorigenicity of interleukin 2-dependent helper T cells transfected with IL-2 gene. J Exp Med 1989;169:13-25.
16. Baldassarre G, Fedele M, Battista S, et al. Onset of natural killer cell lymphomas in transgenic mice carrying a truncated HMGI-C gene by the chronic stimulation of the IL-2 and IL-15 pathway. Proc Natl Acad Sci USA 2001;98:7970-7975.
17. Vink A, Renauld JC, Warnier G, Van Snick J. Interleukin-9 stimulates in vitro growth of mouse thymic lymphomas. Eur J Immunol 1993;23:1134-1138.
18. Renauld JC, van der Lugt N, Vink A, et al. Thymic lymphomas in interleukin 9 transgenic mice. Oncogene 1994;9:1327-1332.
19. Rich BE, Campos-Torres J, Tepper RI, Moreadith RW, Leder P. Cutaneous lymphoproliferation and lymphomas in interleukin 7 transgenic mice. J Exp Med 1993;177:305-316.
20. McMillan DN, Kernohan NM, Flett ME, et al. Interleukin 2 receptor expression and interleukin 2 localisation in human solid tumor cells in situ and in vitro: Evidence for a direct role in the regulation of tumour cell proliferation. Int J Cancer 1995;60:766-772.
21. Shibuya H, Yoneyama M, Ninomiya-Tsuji J, Matsumoto K, Taniguchi T. IL-2 and EGF receptors stimulate the hematopoietic cell cycle via different signaling pathways: Demonstration of a novel role for c-myc. Cell 1992;70:57-67.
22. Lauder A, Castellanos A, Weston K. c-Myb transcription is activated by protein kinase B (PKB) following interleukin 2 stimulation of T cells and is required for PKB-mediated protection from apoptosis. Mol Cell Biol 2001;21:5797-5805.
23. Rohwer F, Todd S, McGuire KL. The effect of IL-2 treatment on transcriptional attenuation in proto-oncogenes pim-1 and c-myb in human thymic blast cells. J Immunol 1996;157:643-649.
24. D'Andrea RJ, Barry SC, Moretti PA, et al. Extracellular truncations of h beta c, the common signaling subunit for interleukin-3 (IL-3), granulocyte-macrophage colony-stimulating factor (GM-CSF), and IL-5, lead to ligand-independent activation. Blood 1996;87:2641-2648.
25. Gonda TJ, D'Andrea RJ. Activating mutations in cytokine receptors: Implications for receptor function and role in disease. Blood 1997;89:355-369.
26. Kono T, Doi T, Yamada G, et al. Murine interleukin 2 receptor beta chain: Dysregulated gene expression in lymphoma line EL-4 caused by a promoter insertion. Proc Natl Acad Sci USA 1990;87:1806-1810.
27. Wong JC, Lee SB, Bell MD, et al. Induction of the interleukin-2/15 receptor beta-chain by the EWS-WT1 translocation product. Oncogene 2002;21:2009-2019.
28. Bosma GC, Davisson MT, Ruetsch NR, Sweet HO, Shultz LD, Bosma MJ. The mouse mutation severe combined immune deficiency (scid) is on chromosome 16. Immunogenetics 1989;29:54-57.
29. Blunt T, Gell D, Fox M, et al. Identification of a nonsense mutation in the carboxyl-terminal region of DNA-dependent protein kinase catalytic subunit in the scid mouse. Proc Natl Acad Sci USA 1996;93:10285-10290.
30. Kuff EL, Lueders KK. The intracisternal A-particle gene family: Structure and functional aspects. Adv Cancer Res 1988;51:183-276.
31. Christy RJ, Huang RC. Functional analysis of the long terminal repeats of intracisternal A-particle genes: Sequences within the U3 region determine both the efficiency and direction of promoter activity. Mol Cell Biol 1988;8:1093-1102.
32. Horowitz M, Luria S, Rechavi G, Givol D. Mechanism of activation of the mouse c-mos oncogene by the LTR of an intracisternal A-particle gene. EMBO J 1984;3:2937-2941.
33. Leslie KB, Lee F, Schrader JW. Intracisternal A-type particle-mediated activations of cytokine genes in a murine myelomonocytic leukemia: Generation of functional cytokine mRNAs by retroviral splicing events. Mol Cell Biol 1991;11:5562-5570.
34. Lee JS, Haruna T, Ishimoto A, Honjo T, Yanagawa S. Intracisternal type A particle-mediated activation of the Notch4/int3 gene in a mouse mammary tumor: Generation of truncated Notch4/int3 mRNAs by retroviral splicing events. J Virol 1999;73:5166-5171.
35. Rosenthal A, Jones DS. Genomic walking and sequencing by oligo-cassette mediated polymerase chain reaction. Nucleic Acids Res 1990;18:3095-3096.
36. Ukai H, Ukai-Tadenuma M, Ogiu T, Tsuji H. A new technique to prevent self-ligation of DNA. J Biotechnol 2002;97:233-242.
37. Mount S. A catalogue of splice junction sequences. Nucleic Acids Res 1982;10:459-472.
38. de Bergeyck V, De Plaen E, Chomez P, Boon T, Van Pel A. An intracisternal A-particle sequence codes for an antigen recognized by syngeneic cytolytic T lymphocytes on a mouse spontaneous leukemia. Eur J Immunol 1994;24:2203-2212.
39. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001;411:342-348.
40. Nakamura Y, Russell SM, Mess SA, et al. Heterodimerization of the IL-2 receptor beta- and gamma-chain cytoplasmic domains is required for signalling. Nature 1994;369:330-333.
41. Lacronique V, Boureux A, Valle VD, et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 1997;278:1309-1312.
42. Garcia R, Jove R. Activation of STAT transcription factors in oncogenic tyrosine kinase signaling. J Biomed Sci 1998;5:79-85.
43. Ward AC, Touw I, Yoshimura A. The Jak-Stat pathway in normal and perturbed hematopoiesis. Blood 2000;95:19-29.
44. Cayuela JM, Gardie B, Sigaux F. Disruption of the multiple tumor suppressor gene MTS1/p16(INK4a)/CDKN2 by illegitimate V(D)J recombinase activity in T-cell acute lymphoblastic leukemias. Blood 1997;90:3720-3726.
45. Brown L, Cheng JT, Chen Q, et al. Site-specific recombination of the tal-1 gene is a common occurrence in human T cell leukemia. EMBO J 1990;9:3343-3351.
46. Azzarone B, Pottin-Clemenceau C, Krief P, et al. Are interleukin-2 and interleukin-15 tumor promoting factors for human non-hematopoietic cells? Eur Cytokine Netw 1996;7:27-36.
47. Eisenman RN. Deconstructing myc. Genes Dev 2001;15:2023-2030.
48. Yasukawa H, Sasaki A, Yoshimura A. Negative regulation of cytokine signaling pathways. Annu Rev Immunol 2000;18:143-164.
49. Yoshikawa H, Matsubara K, Qian GS, et al. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 2001;28:29-35.